- Home
- RM vs CLLS Comparison
RM vs CLLS Comparison
Compare RM & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RM | CLLS |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.4M | 374.2M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RM | CLLS |
|---|---|---|
| Price | $32.20 | $3.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $30.00 | $8.50 |
| AVG Volume (30 Days) | ★ 56.6K | 32.4K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | ★ 7.49 | N/A |
| EPS | ★ 4.45 | N/A |
| Revenue | ★ $645,598,000.00 | N/A |
| Revenue This Year | $12.83 | $40.37 |
| Revenue Next Year | $7.93 | N/A |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $25.41 | $1.10 |
| 52 Week High | $46.00 | $5.48 |
Technical Indicators
Market Signals| Indicator | RM | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 39.37 |
| Support Level | $30.85 | $3.41 |
| Resistance Level | $34.89 | $3.77 |
| Average True Range (ATR) | 1.44 | 0.17 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 23.47 | 2.60 |
Price Performance
Historical ComparisonAbout RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.